The investigations target TPG Mortgage Investment Trust, Accelerant Holdings, Harte Hanks, and Fulcrum Therapeutics. Attorneys at the firm are reviewing potential breaches of fiduciary duty and violations of federal securities laws, citing concerns that current deal terms may stifle superior competing offers.

For TPG Mortgage, the merger with Cherry Hill Mortgage Investment Corporation leaves TPG shareholders with approximately 73% of the combined entity. Accelerant Holdings faces scrutiny regarding its cash sale to Thoma Bravo at $20.25 per share. Harte Hanks investors are being evaluated on their options to receive $5.00 cash or 0.50 shares of Star Equity’s Series A preferred stock. Meanwhile, the Fulcrum Therapeutics merger with Slate Medicines leaves Fulcrum shareholders with a 5% stake in the resulting company. Halper Sadeh, led by Daniel Sadeh and Zachary Halper, stated it may seek increased compensation or further disclosures for investors involved in these transitions.